vs
Side-by-side financial comparison of NNN REIT, INC. (NNN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
NNN REIT, INC. is the larger business by last-quarter revenue ($238.4M vs $196.9M, roughly 1.2× Pacira BioSciences, Inc.). On growth, NNN REIT, INC. posted the faster year-over-year revenue change (9.1% vs 5.1%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 5.2%).
NNN Reit, Inc. is a real estate investment trust that invests primarily in restaurant properties that are subject to long-term triple net leases, usually under leaseback arrangements. It is organized in Maryland with its principal office in Orlando, Florida.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NNN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $238.4M | $196.9M |
| Net Profit | $96.0M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | 62.3% | 1.2% |
| Net Margin | 40.2% | — |
| Revenue YoY | 9.1% | 5.1% |
| Net Profit YoY | -2.0% | — |
| EPS (diluted) | $0.51 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $238.4M | $196.9M | ||
| Q3 25 | $230.2M | $179.5M | ||
| Q2 25 | $226.8M | $181.1M | ||
| Q1 25 | $230.9M | $168.9M | ||
| Q4 24 | $218.5M | $187.3M | ||
| Q3 24 | $218.6M | $168.6M | ||
| Q2 24 | $216.8M | $178.0M | ||
| Q1 24 | $215.4M | $167.1M |
| Q4 25 | $96.0M | — | ||
| Q3 25 | $96.8M | $5.4M | ||
| Q2 25 | $100.5M | $-4.8M | ||
| Q1 25 | $96.5M | $4.8M | ||
| Q4 24 | $97.9M | — | ||
| Q3 24 | $97.9M | $-143.5M | ||
| Q2 24 | $106.7M | $18.9M | ||
| Q1 24 | $94.4M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | 62.3% | 1.2% | ||
| Q3 25 | 64.0% | 3.5% | ||
| Q2 25 | 66.0% | 4.7% | ||
| Q1 25 | 62.3% | 1.2% | ||
| Q4 24 | 65.8% | 13.2% | ||
| Q3 24 | 65.7% | -82.8% | ||
| Q2 24 | 70.2% | 15.9% | ||
| Q1 24 | 64.2% | 7.9% |
| Q4 25 | 40.2% | — | ||
| Q3 25 | 42.1% | 3.0% | ||
| Q2 25 | 44.3% | -2.7% | ||
| Q1 25 | 41.8% | 2.8% | ||
| Q4 24 | 44.8% | — | ||
| Q3 24 | 44.8% | -85.1% | ||
| Q2 24 | 49.2% | 10.6% | ||
| Q1 24 | 43.8% | 5.4% |
| Q4 25 | $0.51 | $0.05 | ||
| Q3 25 | $0.51 | $0.12 | ||
| Q2 25 | $0.54 | $-0.11 | ||
| Q1 25 | $0.51 | $0.10 | ||
| Q4 24 | $0.52 | $0.38 | ||
| Q3 24 | $0.53 | $-3.11 | ||
| Q2 24 | $0.58 | $0.39 | ||
| Q1 24 | $0.52 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $4.4B | $693.1M |
| Total Assets | $9.4B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $238.4M | ||
| Q3 25 | $157.9M | $246.3M | ||
| Q2 25 | $6.0M | $445.9M | ||
| Q1 25 | $5.1M | $493.6M | ||
| Q4 24 | $8.7M | $484.6M | ||
| Q3 24 | $173.5M | $453.8M | ||
| Q2 24 | $2.1M | $404.2M | ||
| Q1 24 | $1.1M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $4.4B | $693.1M | ||
| Q3 25 | $4.4B | $727.2M | ||
| Q2 25 | $4.4B | $757.8M | ||
| Q1 25 | $4.4B | $798.5M | ||
| Q4 24 | $4.4B | $778.3M | ||
| Q3 24 | $4.4B | $749.6M | ||
| Q2 24 | $4.2B | $879.3M | ||
| Q1 24 | $4.2B | $892.2M |
| Q4 25 | $9.4B | $1.3B | ||
| Q3 25 | $9.5B | $1.3B | ||
| Q2 25 | $9.1B | $1.5B | ||
| Q1 25 | $9.0B | $1.6B | ||
| Q4 24 | $8.9B | $1.6B | ||
| Q3 24 | $8.9B | $1.5B | ||
| Q2 24 | $8.7B | $1.6B | ||
| Q1 24 | $8.7B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $667.1M | $43.7M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 22.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 6.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $667.1M | $43.7M | ||
| Q3 25 | $218.3M | $60.8M | ||
| Q2 25 | $119.4M | $12.0M | ||
| Q1 25 | $203.3M | $35.5M | ||
| Q4 24 | $635.5M | $33.1M | ||
| Q3 24 | $206.6M | $53.9M | ||
| Q2 24 | $120.5M | $53.2M | ||
| Q1 24 | $190.7M | $49.1M |
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M | ||
| Q1 24 | — | $46.3M |
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% | ||
| Q1 24 | — | 27.7% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | 6.95× | — | ||
| Q3 25 | 2.25× | 11.20× | ||
| Q2 25 | 1.19× | — | ||
| Q1 25 | 2.11× | 7.37× | ||
| Q4 24 | 6.49× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.13× | 2.82× | ||
| Q1 24 | 2.02× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NNN
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
